ALLK: Allakos Inc. - Summary | Jitta

Allakos Inc.

NASDAQ:ALLK

Notice
Stock data is unavailable or the company’s delisted.
Price
$0.33
Loss Chance
59.6%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (13)
Recent Business Performance (33)
Financial Strength (26)
Return to Shareholders (0)
Competitive Advantage (6)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
1.98
317.77%
1.98
317.77%
COMPANY DESCRIPTION
Allakos Inc. operates as a clinical stage biotechnology company that develops monoclonal antibodies that target immunomodulatory receptors present on the surface of immune effector cells involved in allergy, inflammatory, and proliferative diseases. The company was incorporated in 2012 and is based in San Carlos, California. As of May 15, 2025, Allakos Inc. operates as a subsidiary of Concentra Biosciences, LLC.